|
|
|
|
|
|
| |
|
Over the last two decades, we have established our credentials as Our products emerged among the top three brands in the respective therapeutic segments;
Our products were supported by APIs from Ind-Swift Laboratories, our group company. We manufactured superior products and novel drug delivery systems for which we have received patents from US and European countries.
|
 |
We established a US office to enhance our presence in the world’s largest formulation market. We are taking these initiatives ahead With our international marketing division applying for and obtaining product approvals across various countries.
In view of this, we registered our products in various countries leading to exports and are now working to register our products in 15 more countries across the semi-regulated markets of Asia, Africa and Latin America by the end of this financial year.
We plan to increase our stakeholders' wealth through a prudent strategy comprising business de-risking and increasing the proportion of value added revenues. We expect to achieve this through a number of initiatives: low cost capacity expansion, low conversion costs and increased value addition.
We expect that this will enable us to report profit increases higher than the industry average during a boom and profit declines that are less pronounced than the rest of the industry during a downturn.
|
|
| |
|
